about
Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine designInfection of cells expressing CXCR4 mutants lacking N-glycosylation at the N-terminal extracellular domain is enhanced for R5X4-dualtropic human immunodeficiency virus type-1.Development of dengue virus replicons expressing HIV-1 gp120 and other heterologous genes: a potential future tool for dual vaccination against dengue virus and HIVSIVsm quasispecies adaptation to a new simian host.Novel approaches to inhibit HIV entryThe Neutralizing Activity of Anti-Hepatitis C Virus Antibodies Is Modulated by Specific Glycans on the E2 Envelope ProteinAiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidatesAntibody 2G12 Recognizes Di-Mannose Equivalently in Domain- and Nondomain-Exchanged Forms but Only Binds the HIV-1 Glycan Shield if Domain ExchangedStructural basis for diverse N-glycan recognition by HIV-1–neutralizing V1–V2–directed antibody PG16HIV-1 gp120 as a therapeutic target: navigating a moving labyrinthGlycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodiesAllosteric modulation of the HIV-1 gp120-gp41 association site by adjacent gp120 variable region 1 (V1) N-glycans linked to neutralization sensitivityHuman Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B EnvelopeHuman immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodiesComparison of immunogenicity between codon optimized HIV-1 Thailand subtype B gp140 and gp145 vaccines.Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development.HIV-1 Glycan Density Drives the Persistence of the Mannose Patch within an Infected Individual.Glycan shielding of the influenza virus hemagglutinin contributes to immunopathology in mice.Functional contributions of carbohydrate on AIDS virus glycoproteinNovel monoclonal antibody directed at the receptor binding site on the avian sarcoma and leukosis virus Env complexEvolution of the uniquely adaptable lentiviral envelope in a natural reservoir host.Characterization of glycopeptides from HIV-I(SF2) gp120 by liquid chromatography mass spectrometry.Targeting the carbohydrates on HIV-1: Interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGNGlycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopes' accessibility.Comparison of HPLC/ESI-FTICR MS versus MALDI-TOF/TOF MS for glycopeptide analysis of a highly glycosylated HIV envelope glycoprotein.Immunization with single-cycle SIV significantly reduces viral loads after an intravenous challenge with SIV(mac)239.The phthalocyanine prototype derivative Alcian Blue is the first synthetic agent with selective anti-human immunodeficiency virus activity due to its gp120 glycan-binding potential.Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways.A strategy for eliciting antibodies against cryptic, conserved, conformationally dependent epitopes of HIV envelope glycoproteinGeneration of random mutant libraries with multiple primers in a single reactionEnvelope vaccination shapes viral envelope evolution following simian immunodeficiency virus infection in rhesus monkeys.Protection of macaques with diverse MHC genotypes against a heterologous SIV by vaccination with a deglycosylated live-attenuated SIV.Host-specific modulation of the selective constraints driving human immunodeficiency virus type 1 env gene evolution.Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120.Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopesStrategies used by human immunodeficiency virus that allow persistent viral replication.Variants of human immunodeficiency virus type 1 that efficiently use CCR5 lacking the tyrosine-sulfated amino terminus have adaptive mutations in gp120, including loss of a functional N-glycanCD4-mimetic small molecules sensitize human immunodeficiency virus to vaccine-elicited antibodiesBiologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines.
P2860
Q24679395-D2E98EF6-60CD-4B3D-8AAE-1C0471916823Q24794092-F5D5702E-DD65-4C23-B837-33F03FA6C78DQ24797123-BB394E47-2AFB-427F-90F4-BC239A4434B4Q24817181-377FA959-75D5-40B0-81FC-2BB3C3E4B2AFQ27013957-5A26D25F-7E05-489C-9BB6-FF018E21BB16Q27481009-2C2D1EBF-0DB4-4AAE-9308-94A477FA6BA4Q27489000-98BD40F8-2C9D-4FFD-B7F4-68046D753819Q27664038-7D2E4299-671C-423A-A3E5-0107CFF23552Q27678312-D0E82F78-550D-47B3-90E3-155F58DD2C32Q28086826-1FEF04E5-CD76-4407-A3A2-94FB94C09AB4Q28263932-4C756E30-3B20-4378-8BA8-438662276C31Q28485983-46D908C9-3F71-4DD9-955E-56747B1610E8Q29307502-5ECEFF97-569A-431D-9F89-A218B0C80479Q29619015-04AB55DB-9C91-4A09-93F6-40B7FA27D35CQ30360326-72292C96-787D-4FF9-8625-89FC3F94B253Q30379200-E8FD4BB1-943D-4610-BC3D-B27B4A430B05Q30381447-8C51A8AA-A553-4E1C-B594-3CFE7293082CQ30393763-5D24862E-3E99-41B8-9257-D9936694E647Q30394731-D2EE7CF1-CA49-4A92-95B1-43765BD1282CQ30397572-A5E12CF7-842E-45DE-9DC5-5B4881A3817DQ30453272-CE49AC16-BC00-471A-AA63-97659C3AE416Q31034710-B9E27ACD-0BAE-4DF1-8EF5-387A3F24FE5FQ31123461-54E94BAC-D3EF-4438-B0D1-BE6C1F5934B2Q33321821-F45A3CC1-F981-40A3-9550-E49C58816481Q33323199-F80B1D37-6C98-4A88-AF5B-CBC521B15640Q33345100-8007CD71-79B6-47AB-938C-7D1BD530FD3BQ33402455-8A636B1C-5C48-4D21-BDA5-ED473418453FQ33498727-00E5C16E-8F1E-416C-A901-F225CC35ABA6Q33504599-0D469EF6-5E1A-4D8A-BDBD-261A17CFCED5Q33522232-CAD311AA-F2E5-435D-8121-FBF25DE7C681Q33548933-ACED3E3C-FB1F-46B4-8FA3-75A889EE13CDQ33558407-98853748-4A56-4385-828C-5FB080D13336Q33638458-C1F707F3-A48D-4231-88DD-68A32D7126FEQ33646567-6BB6DA58-2D45-4545-AF61-11F8B484770EQ33648180-9A8AFAD2-DCFB-4DE2-8AC2-923E55282BD8Q33648910-DED852E3-8B69-44D9-9910-71DE4283BF05Q33680601-C86EE414-D9B9-41C8-8A64-9F69D862B51EQ33707333-55CF5E4C-4C64-46C1-A61B-9FF648B7027AQ33743734-6DDEB48A-4F37-429C-811E-89A3DB560632Q33780524-720E800A-E502-4942-AA1A-7A2C2065FD00
P2860
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
A role for carbohydrates in immune evasion in AIDS.
@en
A role for carbohydrates in immune evasion in AIDS.
@nl
type
label
A role for carbohydrates in immune evasion in AIDS.
@en
A role for carbohydrates in immune evasion in AIDS.
@nl
prefLabel
A role for carbohydrates in immune evasion in AIDS.
@en
A role for carbohydrates in immune evasion in AIDS.
@nl
P2093
P2860
P356
P1433
P1476
A role for carbohydrates in immune evasion in AIDS.
@en
P2093
Desrosiers RC
Reitter JN
P2860
P2888
P304
P356
10.1038/NM0698-679
P407
P577
1998-06-01T00:00:00Z
P5875
P6179
1019316535